Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Mast cells and eosinophils in invasive breast carcinoma

Authors: Rose-Marie Amini, Kirsimari Aaltonen, Heli Nevanlinna, Ricardo Carvalho, Laura Salonen, Päivi Heikkilä, Carl Blomqvist

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Inflammatory cells in the tumour stroma has gained increasing interest recently. Thus, we aimed to study the frequency and prognostic impact of stromal mast cells and tumour infiltrating eosinophils in invasive breast carcinomas.

Methods

Tissue microarrays containing 234 cases of invasive breast cancer were prepared and analysed for the presence of stromal mast cells and eosinophils. Tumour infiltrating eosinophils were counted on hematoxylin-eosin slides. Immunostaining for tryptase was done and the total number of mast cells were counted and correlated to the proliferation marker Ki 67, positivity for estrogen and progesterone receptors, clinical parameters and clinical outcome.

Results

Stromal mast cells were found to correlate to low grade tumours and estrogen receptor positivity. There was a total lack of eosinophils in breast cancer tumours.

Conclusion

A high number of mast cells in the tumours correlated to low-grade tumours and estrogen receptor positivity. Eosinophils are not tumour infiltrating in breast cancers.
Appendix
Available only for authorised users
Literature
1.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 17:357 (9255): 539-545. 10.1016/S0140-6736(00)04046-0.CrossRef
2.
Coussens LM, Werb Z: Inflammatory cells and cancer: think different!. J Exp Med. 2001, 19:193 (6): 23-26. 10.1084/jem.193.6.F23.CrossRef
3.
Almholt K, Johnsen M: Stromal cell involvement in cancer. Recent Results Cancer Res. 2003, 162: 31-42.CrossRefPubMed
4.
De Visser KE, Eichten A, Coussens L: Paradoxical roles of the immune system during cancer development. Nature Reviews. 2006, 6: 24-40. 10.1038/nrc1782.PubMed
5.
Dave SS, Wright G, Tan B, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004, 18;351 (21): 2159-2169. 10.1056/NEJMoa041869.CrossRef
6.
Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM, Boohaker EA: Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res. 1983, 43 (6): 2997-3000.PubMed
7.
Enblad G, Sundström C, Glimelius B: Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol. 1993, 11: 187-193. 10.1002/hon.2900110404.CrossRefPubMed
8.
Moezzi J, Gopalswamy N, Haas RJ, Markert RJ, Suryaprasad S, Bhutani MS: Stromal eosinophilia in colonic epithelial neoplasms. Am J Gastroenterol. 2000, 95 (2): 520-523. 10.1111/j.1572-0241.2000.01778.x.CrossRefPubMed
9.
Ishibashi S, Ohashi Y, Suzuki T, Miyazaki S, Moriya T, Satomi S, Sasano H: Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res. 2006, 26: 1419-1424.PubMed
10.
Lowe D, Jorizzo J, Hutt MS: Tumour-associated eosinophilia: a review. J Clin Pathol. 1981, 34 (12): 1343-1348. 10.1136/jcp.34.12.1343.CrossRefPubMed
11.
van Driel WJ, Hogendoorn PCW, Jansen F-W, Zwinderman AH, Trimbos JB, Fleuren GJ: Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Human Pathol. 1996, 27 (9): 904-911. 10.1016/S0046-8177(96)90216-6.CrossRef
12.
Samoszuk M, Kanakubo E, Chan JK: Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer. 2005, 21: 121-10.1186/1471-2407-5-121.CrossRef
13.
Gooch JL, Lee AV, Yee D: Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 1998, 15;58 (18): 4199-4205.
14.
Theoharides TC, Conti P: Mast cells: the Jekyll and Hyde of tumor growth. Trends in Immunology. 2004, 25 (5): 235-241. 10.1016/j.it.2004.02.013.CrossRefPubMed
15.
Aaltomaa S, Lipponen P, Papinaho S, Kosma VM: Mast cells in breast cancer. Anticancer Res. 1993, 13 (3): 785-788.PubMed
16.
Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M: The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 2004, 17 (6): 690-695. 10.1038/modpathol.3800094.CrossRefPubMed
17.
Rajput AB, Turbin DA, Cheang MCU, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG: Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2007 Mar 13
18.
Bowers HM, Mahapatro RC, Kenedy JW: Number of mast cells in the axillary lymph nodes of breast cancer patients. Cancer. 1979, 43: 568-573. 10.1002/1097-0142(197902)43:2<568::AID-CNCR2820430225>3.0.CO;2-#.CrossRefPubMed
19.
Naik R, Baliga P, Bansal R, Pai M: Distribution of mast cells in the axillary lymph nodes of breast cancer patients. J Indian Med Assoc. 1997, 95 (12): 606-607.PubMed
20.
Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G: The role of human mast cell derived cytokines in eosinophil biology. J Interferon and Cytokine Res. 2004, 24: 271-281. 10.1089/107999004323065057.CrossRef
21.
Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C, Enblad G: Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002, 119 (1): 122-124. 10.1046/j.1365-2141.2002.03768.x.CrossRefPubMed
22.
Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G: Mast cells express functional CD30 ligand and are the predominant CD30 L-positive cells in Hodgkin's disease. Br J Haematol. 2001, 114: 616-623. 10.1046/j.1365-2141.2001.02977.x.CrossRefPubMed
23.
Syrjäkoski K, Vahteristo P, Eerola HA, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi O, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000, 92: 1529-1531. 10.1093/jnci/92.18.1529.CrossRefPubMed
24.
Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H: Histopathological features of breast tumours in BRCA1, BRCA2, and inmutation negative breast cancer families. Breast Cancer Res. 2004, 7: 93-100. 10.1186/bcr953.CrossRef
25.
Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H: Breast cancer patients with p53 PRO72-homozygous genotype have a poorer survival. Clin Cancer Res. 2005, 15 (14): 5098-5103. 10.1158/1078-0432.CCR-05-0173.CrossRef
26.
Wood GS, Warnke R: Suppression of endogenous avidin binding activity in tissues and its relevance to biotin-avidin detection systems. J Histochem Cytochem. 1981, 29: 1196-1204.CrossRefPubMed
27.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of the histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
28.
Nemoto T, Natarajan N, Bedwani R, Vana J, Murphy GP: Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer. 1983, 15;51 (8): 1333-1338. 10.1002/1097-0142(19830415)51:8<1333::AID-CNCR2820510802>3.0.CO;2-T.CrossRef
29.
Tan S-Y, Fan Y, Luo H-S, Shen Z-X, Guo Y, Zhao L-J: Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005, 11 (8): 1210-1214.CrossRefPubMed
30.
Takanami I, Takeuchi K, Naruke M: Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000, 15: 2686-2692. 10.1002/1097-0142(20000615)88:12<2686::AID-CNCR6>3.0.CO;2-6.CrossRef
31.
Tomita M, Matsuzaki Y, Onitsuka T: Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000, 69: 1686-1690. 10.1016/S0003-4975(00)01160-7.CrossRefPubMed
32.
Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A: Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumour stage in non-small cell lungcarcinomas. Lung Cancer. 2004, 43 (1): 47-54. 10.1016/j.lungcan.2003.08.013.CrossRefPubMed
33.
Elpek GO, Gelen T, Aksoy NH, Erdogan A, Dertsiz L, Demircan A, Keles N: The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001, 54 (12): 940-944.CrossRefPubMed
34.
Benitez-Bribiesca L, Wong A, Utrera D, Castellanos E: The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem. 2001, 49 (8): 1061-1062.CrossRefPubMed
35.
Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003, 33 (5): 420-425. 10.1046/j.1365-2362.2003.01152.x.CrossRefPubMed
Metadata
Title
Mast cells and eosinophils in invasive breast carcinoma
Authors
Rose-Marie Amini
Kirsimari Aaltonen
Heli Nevanlinna
Ricardo Carvalho
Laura Salonen
Päivi Heikkilä
Carl Blomqvist
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-165

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Factors associated with quality of life of outpatients with breast cancer and gynecologic cancers and their family caregivers: a controlled study

Research article

Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study

Research article

Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population – a cross-sectional study

Study protocol

Improving the quality and efficiency of follow-up after curative treatment for breast cancer – rationale and study design of the MaCare trial

Research article

The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis

Research article

Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits